NCT06979271View on ClinicalTrials.gov

Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions
TelitaciceptTreatment ComplianceRheumatoid Arthritis
Interventions
DRUG

Telitacicept Tofacitinib

One group of D2TRA subjects receive Telitacicept combine Tofacitinib treatment

Trial Locations (1)

310000

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Provincial People's Hospital

OTHER

NCT06979271 - Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter